There’ll Be No Follow-On Biologics in the U.S. At All...

The IN VIVO Blog -- ...At least not if anything close to the Eshoo bill—one of two versions of biosimilar legislation currently before the House of Representatives—gets approved, according to Hannes Teissl, head of Sandoz’s Biopharmaceuticals unit.